A share price of Grifols SA ADR [GRFS] is currently trading at $6.78, up 7.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The GRFS shares have gain 17.71% over the last week, with a monthly amount drifted -22.51%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 14, February 2024, Grifols announces positive topline phase 3 fibrinogen clinical trial results. In a post published today on Yahoo Finance, In the AdFIrst study, Biotest’s fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profile.
From an analyst’s perspective:
Grifols SA ADR [NASDAQ: GRFS] stock has seen the most recent analyst activity on March 12, 2024, when Deutsche Bank downgraded its rating to a Sell. Previously, Morgan Stanley upgraded its rating to Overweight on April 12, 2023. On March 03, 2023, downgrade downgraded it’s rating to Equal-Weight. Barclays upgraded its rating to a Equal Weight. Jefferies upgraded its rating to a Buy. In a note dated November 05, 2021, Deutsche Bank downgraded an Hold rating on this stock.
Grifols SA ADR experienced fluctuations in its stock price throughout the past year between $5.30 and $12.15. Grifols SA ADR [NASDAQ: GRFS] shares were valued at $6.78 at the most recent close of the market.
Analyzing the GRFS fundamentals
Trailing Twelve Months sales for Grifols SA ADR [NASDAQ:GRFS] were 7.13B which represents 3.81% growth. Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.01 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.11 points at the first support level, and at 5.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.13, and for the 2nd resistance point, it is at 7.49.
Grifols SA ADR [GRFS] reported earnings per share of $0.15 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.24/share, meaning a difference of -$0.09 and a surprise factor of -37.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.12 per share as compared to estimates of $0.24 per share, a difference of -$0.12 representing a surprise of -50.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Grifols SA ADR [NASDAQ:GRFS] is 2.79. On the other hand, the Quick Ratio is 1.29, and the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 0.24, the price to book ratio is 0.27 and price to earnings (TTM) ratio is 71.75.
